STOCK TITAN

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences AI
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Matthias Alder will participate in a panel at the AI Driven Drug Discovery Summit on December 6, 2023. The event will focus on collaboration in AI-driven drug discovery.
Positive
  • None.
Negative
  • None.

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023.

AI Driven Drug Discovery Summit
Date: Wednesday, December 6, 2023
Time: 4:30 p.m. EST
Format: Panel Discussion – Collaboration is Key to Enhancing AI-Driven Drug Discovery

To register for the event, please click here.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.

Leveraging AI-supported structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company’s SEE-Tx® discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology. For more information, please visit GainTherapeutics.com and follow us on LinkedIn.

Investor & Media Contact:

Susan Sharpe
Linnden Communications
(919) 602-2330
susan@linndencom.com


FAQ

What is Gain Therapeutics, Inc.'s ticker symbol?

Gain Therapeutics, Inc.'s ticker symbol is GANX.

When and where will Matthias Alder participate in a panel discussion?

Matthias Alder will participate in a panel discussion at the AI Driven Drug Discovery Summit on December 6, 2023, at the Sheraton Boston Hotel in Boston, Massachusetts.

What is the focus of the AI Driven Drug Discovery Summit?

The AI Driven Drug Discovery Summit will focus on collaboration in AI-driven drug discovery.

How can I register for the AI Driven Drug Discovery Summit?

To register for the event, please click here.

Gain Therapeutics, Inc.

NASDAQ:GANX

GANX Rankings

GANX Latest News

GANX Stock Data

48.17M
14.26M
16.45%
10.33%
0.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BETHESDA

About GANX

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.